Blog
RSS FeedPosted by Michael Wonder on 16 May 2024
It is time to reconsider the 3% discount rate
15 May 2024 - Health technology assessment guidance often recommends a 3% real annual discount rate, the appropriateness of which ...
Posted by Michael Wonder on 11 Apr 2024
170,000 people in England to have further treatment choice for preventing migraine attacks
11 April 2024 - In final draft guidance published today NICE has recommended atogepant, the first of a new type of ...
Posted by Michael Wonder on 11 Apr 2024
Children and young adults to benefit after NICE recommends personalised immunotherapy to treat blood cancer be made routinely available on the NHS
11 April 2024 - Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia. ...
Posted by Michael Wonder on 11 Apr 2024
'Really expensive': migraine expert calls for more funded treatments
10 April 2024 - Migraine experts are advocating for PHARMAC to fund a new generation of migraine drugs that target ...
Posted by Michael Wonder on 10 Apr 2024
Why won’t health insurance companies pay for new drugs?
10 April 2024 - The FDA is doing its part to fast-track new treatments, but insurers are standing in the way ...
Posted by Michael Wonder on 10 Apr 2024
AdrenoMed receives FDA fast track designation for enibarcimab for treatment of septic shock
10 April 2024 - AdrenoMed today announced that the US FDA has granted fast track designation to its lead product candidate ...
Posted by Michael Wonder on 10 Apr 2024
ICER releases draft evidence report on treatment for chronic obstructive pulmonary disease
10 April 2024 - Public comment period now open until 7 May 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 10 Apr 2024
New target zero initiative aims to help improve access to new drugs
9 April 2024 - Target Zero is a new initiative that aims to improve the time to access for patients ...
Posted by Michael Wonder on 10 Apr 2024
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
3 April 2024 - AB Science today announced that Health Canada has granted eligibility for reconsideration request for masitinib in ...
Posted by Michael Wonder on 10 Apr 2024
FDA accepts filing of new drug application for nalmefene auto-injector for the treatment of known or suspected opioid overdose
8 April 2024 - Purdue Pharma announced today that FDA has accepted for filing the company’s new drug application for the ...
Posted by Michael Wonder on 10 Apr 2024
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
9 April 2024 - Lundbeck and Otsuka have submitted a supplemental new drug application for US FDA review of brexpiprazole ...
Posted by Michael Wonder on 10 Apr 2024
Calls for supplement to treat rare metabolic disorder to be relisted on PBS
10 April 2024 - An Adelaide mother says a vital supplement that assists her sons with a rare metabolic disorder ...
Posted by Michael Wonder on 10 Apr 2024
Mum’s plea: ‘I’m dying but $7.70 could save my kids’
10 April 2024 - Amelia Ramsay has battled all her life – and now she may have to watch her kids ...
Posted by Michael Wonder on 10 Apr 2024
Cabozantinib maleate in combination with nivolumab for the first-line treatment of patients with advanced renal cell carcinoma
10 April 2024 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) in combination with ...
Posted by Michael Wonder on 10 Apr 2024
Making tender decisions: how does PHARMAC allocate its fixed budget?
10 April 2024 - The annual tender is one of several mechanisms PHARMAC uses to manage how much New Zealand ...
Posted by Michael Wonder on 09 Apr 2024
Syros receives fast track designation from the FDA for tamibarotene for the treatment of newly diagnosed unfit AML with RARA gene over-expression
9 April 2024 - Syros Pharmaceuticals today announced that the US FDA has granted fast track designation to tamibarotene in ...